NewAmsterdam Pharma (NAMS) Retained Earnings (2021 - 2026)
NewAmsterdam Pharma (NAMS) reported Retained Earnings of -$810.8 million for Q1 2026, down 18386.67% on a YoY basis from N/an in Q1 2025, and down 17016.98% sequentially from $4.8 million in Q4 2025.
NewAmsterdam Pharma (NAMS) Retained Earnings (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 6 years of Retained Earnings data on file, last reported at -$810.8 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 18386.67% year-over-year to -$810.8 million; the trailing twelve-month figure through Mar 2026 stood at -$810.8 million (down 18386.67% YoY), and the FY2025 full-year result was $4.8 million, up 7.3% from the prior year.
- Retained Earnings fell to -$810.8 million in Q1 2026, from $4.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $4.8 million in Q4 2025 to a low of -$810.8 million in Q1 2026.
- A 5-year average of -$240.6 million and a median of -$58.7 million in 2022 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings soared 103.63% in 2023 and plunged 18386.67% in 2026, its largest moves.
- Tracing NAMS's Retained Earnings over 5 years: stood at -$121.8 million in 2022, then jumped by 103.63% to $4.4 million in 2023, then climbed by 1.02% to $4.5 million in 2024, then grew by 7.3% to $4.8 million in 2025, then slumped by 17016.98% to -$810.8 million in 2026.
- Business Quant data shows NAMS's Retained Earnings at -$810.8 million in Q1 2026, $4.8 million in Q4 2025, and -$687.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | -810.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -810.83 Mn |
| Dec 31, 2025 | 4.79 Mn |
| Sep 30, 2025 | -687.47 Mn |
| Jun 30, 2025 | -615.46 Mn |
| Mar 31, 2025 | 4.43 Mn |
| Dec 31, 2024 | 4.47 Mn |
| Sep 30, 2024 | -466.39 Mn |
| Jun 30, 2024 | 4.42 Mn |
| Mar 31, 2024 | 4.42 Mn |
| Dec 31, 2023 | 4.42 Mn |
| Jun 30, 2023 | -211.76 Mn |
| Dec 31, 2022 | -121.78 Mn |
| Dec 31, 2021 | 676,086.83 |